MSU Crystals Enhance TDB-Mediated Inflammatory Macrophage IL-1β Secretion

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Tumour microenvironments are rich in macrophages, with M1-like (pro-inflammatory) and M2-like (anti-inflammatory) phenotypes.
• Trehalose-6,6'-dibehenate (TDB) exhibits anti-tumour effects by stimulating M1-like macrophages via Mincle, leading to IL-1β production.

Purpose of the Study:

• To investigate if monosodium urate (MSU), a vaccine adjuvant, can enhance IL-1β production by TDB-stimulated macrophages.
• To explore the potential of MSU/TDB co-treatment for boosting anti-tumour immunity.

Main Methods:

• Differentiated mouse bone marrow macrophages (BMMs) into M1-like (GM-CSF) and M2-like (M-CSF/IL-4) phenotypes.
• Co-treated macrophages with MSU and TDB, assessing IL-1β production.
• Utilized Western blot for pro-IL-1β expression and flow cytometry for macrophage subpopulations (CD86, MHC II).

Main Results:

• MSU/TDB co-treatment significantly enhanced IL-1β production in M1-like (GM-CSF) BMMs, dependent on Mincle.
• TDB, not MSU, induced pro-IL-1β expression.
• Co-stimulation expanded CD86/MHC II subpopulations, with CD86low/MHC IIlow cells showing increased IL-1β production.

Conclusions:

• MSU/TDB co-treatment potentiates Mincle-mediated IL-1β production in M1-like macrophages.
• This combination therapy shows promise for enhancing IL-1β-driven anti-tumour activity within the tumour microenvironment.